Press Releases and Statements
Read our latest company news and announcements
Press Releases
Filter and Search
Newly Published Data Supports Effectiveness of BIOTRONIK Neuro’s RESONANCE™ Stimulation
Results from the BENEFIT-02 trial – the first of its kind to clinically evaluate a multiphase stimulation paradigm – support the effectiveness of RESONANCE multiphase stimulation used in the BIOTRONIK Neuro Prospera™ spinal cord stimulation (SCS) System in the treatment of patients with chronic pain. In contrast to other currently available SCS therapies, RESONANCE requires less power and uses a proprietary integrated circuit design to deliver a continuous, spatially and temporally distributed therapeutic pulse pattern across the spinal cord. Results of the study were recently published in Neuromodulation.1
The prospective, multicenter, randomized, single-blind, feasibility study assessed the safety and effectiveness of BIOTRONIK’s new charge-distributed multiphase stimulation paradigm during an extended SCS trial. It included participants with chronic low back and/or leg pain and baseline numerical rating scale (NRS) for overall pain intensity ≥6. After a successful commercial SCS trial, participants were randomized to multiphase SCS therapy (A: approx. 600–1500 Hz or B: approx. 300–600 Hz). Following washout, therapy was delivered via an investigational external pulse generator and existing leads during an 11- to 12–day testing period.
Among the 65 patients completing the study, there was no statistically significant difference in mean NRS reduction or percent pain relief between multiphase therapies A and B. In the at-home setting, 63.9% of participants reported greater pain relief with multiphase than with commercial SCS therapy, along with an increase in average sleep quality and physical activity. Additionally, adverse events were rare, and none were classified by investigators as serious. On average, multiphase required less power than did commercial therapies.1
BENEFIT-02 is part of a comprehensive research program that supports BIOTRONIK’s Prospera SCS System, which received FDA approval in March 2023. Prospera not only features the first and only RESONANCE multiphase stimulation paradigm, it also includes Embrace One™ – a patient-centric care model that enables proactive care* through automatic, objective, daily remote monitoring.
“Former studies have shown good results with previously commercialized SCS technology, yet in practice we are still looking for ways to reduce patient burden and improve outcomes,” said Dr. Leonardo Kapural, pain physician at the Carolinas Pain Institute and Center for Clinical Research in Winston-Salem, North Carolina, USA and Principal Investigator of the BENEFIT-02 study. “This study is particularly exciting because it’s the first in a series to explore how to do that. The short-term multiphase stimulation results here – combined with early findings from the long-term BENEFIT-03 study – show great promise for the future of SCS.”
BENEFIT-03 is the first long-term evaluation of the Prospera SCS system with RESONANCE multiphase stimulation; automatic, daily, objective, device monitoring; and remote programming. Interim results from the ongoing study in Australia support BIOTRONIK Neuro’s proactive care approach to SCS therapy. Interim six-month results recently presented at the ASPN Annual Conference demonstrated significant pain reduction in both in-clinic and at-home settings with less severe disability.2
“As we await additional data from our BENEFIT-03 study, we're excited to see these initial data on the long-term effects of our SCS system,” said BIOTRONIK Neuro President Todd Langevin. “We developed Prospera to offer patients sustainable pain relief – and we believe its proactive care model will have a clinically meaningful impact on lowering long-term failure rates and reducing the service burden of SCS.”
- END -
References
1 Kapural L, Patterson DG, Li S, Hatheway J, Hunter C, Rosen S, Fishman M, Gupta M, Sayed D, Christopher A, Burgher A, McJunkin T, Ross EL, Provenzano D, Amirdelfan K. Multiphase Spinal Cord Stimulation in Participants With Chronic Back or Leg Pain: Results of the BENEFIT-02 Randomized Clinical Trial, Neuromodulation: Technology at the Neural Interface, 2023, https://doi.org/10.1016/j.neurom.2023.05.006.
2 Russo M, Yu J, Mohabbati V, Amirdelfan K, Kapural L, Verrills P. An implantable SCS system with multiphase stimulation and remote device management: Interim 6-month study results. Poster presented at: The American Society of Pain & Neuroscience July 13-16, 2023; Miami Beach, FL.
Prospera SCS system is not CE marked and not available for sale in CE accepting markets or other geographies outside of the United States.
Embrace One is a support platform intended to help manage a patient’s experience with spinal cord stimulation. It is not intended to be used for medical diagnosis or medical treatment.
*BIOTRONIK Neuro’s remote support team may reach out to patients to ensure proper usage of the spinal cord stimulator based on remotely monitored data. BIOTRONIK Neuro does not provide health advice or clinical actions outside the scope of spinal cord stimulator proper usage. This product support is not a replacement for the patient’s responsibility to communicate any medical questions or concerns with the physician’s office.
Newly Published Data Supports Effectiveness of BIOTRONIK Neuro’s RESONANCE™ Stimulation
Results from the BENEFIT-02 trial – the first of its kind to clinically evaluate a multiphase stimulation paradigm – support the effectiveness of RESONANCE multiphase stimulation used in the BIOTRONIK Neuro Prospera™ spinal cord stimulation (SCS) System in the treatment of patients with chronic pain. In contrast to other currently available SCS therapies, RESONANCE requires less power and uses a proprietary integrated circuit design to deliver a continuous, spatially and temporally distributed therapeutic pulse pattern across the spinal cord. Results of the study were recently published in Neuromodulation.1
The prospective, multicenter, randomized, single-blind, feasibility study assessed the safety and effectiveness of BIOTRONIK’s new charge-distributed multiphase stimulation paradigm during an extended SCS trial. It included participants with chronic low back and/or leg pain and baseline numerical rating scale (NRS) for overall pain intensity ≥6. After a successful commercial SCS trial, participants were randomized to multiphase SCS therapy (A: approx. 600–1500 Hz or B: approx. 300–600 Hz). Following washout, therapy was delivered via an investigational external pulse generator and existing leads during an 11- to 12–day testing period.
Among the 65 patients completing the study, there was no statistically significant difference in mean NRS reduction or percent pain relief between multiphase therapies A and B. In the at-home setting, 63.9% of participants reported greater pain relief with multiphase than with commercial SCS therapy, along with an increase in average sleep quality and physical activity. Additionally, adverse events were rare, and none were classified by investigators as serious. On average, multiphase required less power than did commercial therapies.1
BENEFIT-02 is part of a comprehensive research program that supports BIOTRONIK’s Prospera SCS System, which received FDA approval in March 2023. Prospera not only features the first and only RESONANCE multiphase stimulation paradigm, it also includes Embrace One™ – a patient-centric care model that enables proactive care* through automatic, objective, daily remote monitoring.
“Former studies have shown good results with previously commercialized SCS technology, yet in practice we are still looking for ways to reduce patient burden and improve outcomes,” said Dr. Leonardo Kapural, pain physician at the Carolinas Pain Institute and Center for Clinical Research in Winston-Salem, North Carolina, USA and Principal Investigator of the BENEFIT-02 study. “This study is particularly exciting because it’s the first in a series to explore how to do that. The short-term multiphase stimulation results here – combined with early findings from the long-term BENEFIT-03 study – show great promise for the future of SCS.”
BENEFIT-03 is the first long-term evaluation of the Prospera SCS system with RESONANCE multiphase stimulation; automatic, daily, objective, device monitoring; and remote programming. Interim results from the ongoing study in Australia support BIOTRONIK Neuro’s proactive care approach to SCS therapy. Interim six-month results recently presented at the ASPN Annual Conference demonstrated significant pain reduction in both in-clinic and at-home settings with less severe disability.2
“As we await additional data from our BENEFIT-03 study, we're excited to see these initial data on the long-term effects of our SCS system,” said BIOTRONIK Neuro President Todd Langevin. “We developed Prospera to offer patients sustainable pain relief – and we believe its proactive care model will have a clinically meaningful impact on lowering long-term failure rates and reducing the service burden of SCS.”
- END -
References
1 Kapural L, Patterson DG, Li S, Hatheway J, Hunter C, Rosen S, Fishman M, Gupta M, Sayed D, Christopher A, Burgher A, McJunkin T, Ross EL, Provenzano D, Amirdelfan K. Multiphase Spinal Cord Stimulation in Participants With Chronic Back or Leg Pain: Results of the BENEFIT-02 Randomized Clinical Trial, Neuromodulation: Technology at the Neural Interface, 2023, https://doi.org/10.1016/j.neurom.2023.05.006.
2 Russo M, Yu J, Mohabbati V, Amirdelfan K, Kapural L, Verrills P. An implantable SCS system with multiphase stimulation and remote device management: Interim 6-month study results. Poster presented at: The American Society of Pain & Neuroscience July 13-16, 2023; Miami Beach, FL.
Prospera SCS system is not CE marked and not available for sale in CE accepting markets or other geographies outside of the United States.
Embrace One is a support platform intended to help manage a patient’s experience with spinal cord stimulation. It is not intended to be used for medical diagnosis or medical treatment.
*BIOTRONIK Neuro’s remote support team may reach out to patients to ensure proper usage of the spinal cord stimulator based on remotely monitored data. BIOTRONIK Neuro does not provide health advice or clinical actions outside the scope of spinal cord stimulator proper usage. This product support is not a replacement for the patient’s responsibility to communicate any medical questions or concerns with the physician’s office.
Newly Published Data Supports Effectiveness of BIOTRONIK Neuro’s RESONANCE™ Stimulation
Results from the BENEFIT-02 trial – the first of its kind to clinically evaluate a multiphase stimulation paradigm – support the effectiveness of RESONANCE multiphase stimulation used in the BIOTRONIK Neuro Prospera™ spinal cord stimulation (SCS) System in the treatment of patients with chronic pain. In contrast to other currently available SCS therapies, RESONANCE requires less power and uses a proprietary integrated circuit design to deliver a continuous, spatially and temporally distributed therapeutic pulse pattern across the spinal cord. Results of the study were recently published in Neuromodulation.1
The prospective, multicenter, randomized, single-blind, feasibility study assessed the safety and effectiveness of BIOTRONIK’s new charge-distributed multiphase stimulation paradigm during an extended SCS trial. It included participants with chronic low back and/or leg pain and baseline numerical rating scale (NRS) for overall pain intensity ≥6. After a successful commercial SCS trial, participants were randomized to multiphase SCS therapy (A: approx. 600–1500 Hz or B: approx. 300–600 Hz). Following washout, therapy was delivered via an investigational external pulse generator and existing leads during an 11- to 12–day testing period.
Among the 65 patients completing the study, there was no statistically significant difference in mean NRS reduction or percent pain relief between multiphase therapies A and B. In the at-home setting, 63.9% of participants reported greater pain relief with multiphase than with commercial SCS therapy, along with an increase in average sleep quality and physical activity. Additionally, adverse events were rare, and none were classified by investigators as serious. On average, multiphase required less power than did commercial therapies.1
BENEFIT-02 is part of a comprehensive research program that supports BIOTRONIK’s Prospera SCS System, which received FDA approval in March 2023. Prospera not only features the first and only RESONANCE multiphase stimulation paradigm, it also includes Embrace One™ – a patient-centric care model that enables proactive care* through automatic, objective, daily remote monitoring.
“Former studies have shown good results with previously commercialized SCS technology, yet in practice we are still looking for ways to reduce patient burden and improve outcomes,” said Dr. Leonardo Kapural, pain physician at the Carolinas Pain Institute and Center for Clinical Research in Winston-Salem, North Carolina, USA and Principal Investigator of the BENEFIT-02 study. “This study is particularly exciting because it’s the first in a series to explore how to do that. The short-term multiphase stimulation results here – combined with early findings from the long-term BENEFIT-03 study – show great promise for the future of SCS.”
BENEFIT-03 is the first long-term evaluation of the Prospera SCS system with RESONANCE multiphase stimulation; automatic, daily, objective, device monitoring; and remote programming. Interim results from the ongoing study in Australia support BIOTRONIK Neuro’s proactive care approach to SCS therapy. Interim six-month results recently presented at the ASPN Annual Conference demonstrated significant pain reduction in both in-clinic and at-home settings with less severe disability.2
“As we await additional data from our BENEFIT-03 study, we're excited to see these initial data on the long-term effects of our SCS system,” said BIOTRONIK Neuro President Todd Langevin. “We developed Prospera to offer patients sustainable pain relief – and we believe its proactive care model will have a clinically meaningful impact on lowering long-term failure rates and reducing the service burden of SCS.”
- END -
References
1 Kapural L, Patterson DG, Li S, Hatheway J, Hunter C, Rosen S, Fishman M, Gupta M, Sayed D, Christopher A, Burgher A, McJunkin T, Ross EL, Provenzano D, Amirdelfan K. Multiphase Spinal Cord Stimulation in Participants With Chronic Back or Leg Pain: Results of the BENEFIT-02 Randomized Clinical Trial, Neuromodulation: Technology at the Neural Interface, 2023, https://doi.org/10.1016/j.neurom.2023.05.006.
2 Russo M, Yu J, Mohabbati V, Amirdelfan K, Kapural L, Verrills P. An implantable SCS system with multiphase stimulation and remote device management: Interim 6-month study results. Poster presented at: The American Society of Pain & Neuroscience July 13-16, 2023; Miami Beach, FL.
Prospera SCS system is not CE marked and not available for sale in CE accepting markets or other geographies outside of the United States.
Embrace One is a support platform intended to help manage a patient’s experience with spinal cord stimulation. It is not intended to be used for medical diagnosis or medical treatment.
*BIOTRONIK Neuro’s remote support team may reach out to patients to ensure proper usage of the spinal cord stimulator based on remotely monitored data. BIOTRONIK Neuro does not provide health advice or clinical actions outside the scope of spinal cord stimulator proper usage. This product support is not a replacement for the patient’s responsibility to communicate any medical questions or concerns with the physician’s office.
Newly Published Data Supports Effectiveness of BIOTRONIK Neuro’s RESONANCE™ Stimulation
Results from the BENEFIT-02 trial – the first of its kind to clinically evaluate a multiphase stimulation paradigm – support the effectiveness of RESONANCE multiphase stimulation used in the BIOTRONIK Neuro Prospera™ spinal cord stimulation (SCS) System in the treatment of patients with chronic pain. In contrast to other currently available SCS therapies, RESONANCE requires less power and uses a proprietary integrated circuit design to deliver a continuous, spatially and temporally distributed therapeutic pulse pattern across the spinal cord. Results of the study were recently published in Neuromodulation.1
The prospective, multicenter, randomized, single-blind, feasibility study assessed the safety and effectiveness of BIOTRONIK’s new charge-distributed multiphase stimulation paradigm during an extended SCS trial. It included participants with chronic low back and/or leg pain and baseline numerical rating scale (NRS) for overall pain intensity ≥6. After a successful commercial SCS trial, participants were randomized to multiphase SCS therapy (A: approx. 600–1500 Hz or B: approx. 300–600 Hz). Following washout, therapy was delivered via an investigational external pulse generator and existing leads during an 11- to 12–day testing period.
Among the 65 patients completing the study, there was no statistically significant difference in mean NRS reduction or percent pain relief between multiphase therapies A and B. In the at-home setting, 63.9% of participants reported greater pain relief with multiphase than with commercial SCS therapy, along with an increase in average sleep quality and physical activity. Additionally, adverse events were rare, and none were classified by investigators as serious. On average, multiphase required less power than did commercial therapies.1
BENEFIT-02 is part of a comprehensive research program that supports BIOTRONIK’s Prospera SCS System, which received FDA approval in March 2023. Prospera not only features the first and only RESONANCE multiphase stimulation paradigm, it also includes Embrace One™ – a patient-centric care model that enables proactive care* through automatic, objective, daily remote monitoring.
“Former studies have shown good results with previously commercialized SCS technology, yet in practice we are still looking for ways to reduce patient burden and improve outcomes,” said Dr. Leonardo Kapural, pain physician at the Carolinas Pain Institute and Center for Clinical Research in Winston-Salem, North Carolina, USA and Principal Investigator of the BENEFIT-02 study. “This study is particularly exciting because it’s the first in a series to explore how to do that. The short-term multiphase stimulation results here – combined with early findings from the long-term BENEFIT-03 study – show great promise for the future of SCS.”
BENEFIT-03 is the first long-term evaluation of the Prospera SCS system with RESONANCE multiphase stimulation; automatic, daily, objective, device monitoring; and remote programming. Interim results from the ongoing study in Australia support BIOTRONIK Neuro’s proactive care approach to SCS therapy. Interim six-month results recently presented at the ASPN Annual Conference demonstrated significant pain reduction in both in-clinic and at-home settings with less severe disability.2
“As we await additional data from our BENEFIT-03 study, we're excited to see these initial data on the long-term effects of our SCS system,” said BIOTRONIK Neuro President Todd Langevin. “We developed Prospera to offer patients sustainable pain relief – and we believe its proactive care model will have a clinically meaningful impact on lowering long-term failure rates and reducing the service burden of SCS.”
- END -
References
1 Kapural L, Patterson DG, Li S, Hatheway J, Hunter C, Rosen S, Fishman M, Gupta M, Sayed D, Christopher A, Burgher A, McJunkin T, Ross EL, Provenzano D, Amirdelfan K. Multiphase Spinal Cord Stimulation in Participants With Chronic Back or Leg Pain: Results of the BENEFIT-02 Randomized Clinical Trial, Neuromodulation: Technology at the Neural Interface, 2023, https://doi.org/10.1016/j.neurom.2023.05.006.
2 Russo M, Yu J, Mohabbati V, Amirdelfan K, Kapural L, Verrills P. An implantable SCS system with multiphase stimulation and remote device management: Interim 6-month study results. Poster presented at: The American Society of Pain & Neuroscience July 13-16, 2023; Miami Beach, FL.
Prospera SCS system is not CE marked and not available for sale in CE accepting markets or other geographies outside of the United States.
Embrace One is a support platform intended to help manage a patient’s experience with spinal cord stimulation. It is not intended to be used for medical diagnosis or medical treatment.
*BIOTRONIK Neuro’s remote support team may reach out to patients to ensure proper usage of the spinal cord stimulator based on remotely monitored data. BIOTRONIK Neuro does not provide health advice or clinical actions outside the scope of spinal cord stimulator proper usage. This product support is not a replacement for the patient’s responsibility to communicate any medical questions or concerns with the physician’s office.
Newly Published Data Supports Effectiveness of BIOTRONIK Neuro’s RESONANCE™ Stimulation
Results from the BENEFIT-02 trial – the first of its kind to clinically evaluate a multiphase stimulation paradigm – support the effectiveness of RESONANCE multiphase stimulation used in the BIOTRONIK Neuro Prospera™ spinal cord stimulation (SCS) System in the treatment of patients with chronic pain. In contrast to other currently available SCS therapies, RESONANCE requires less power and uses a proprietary integrated circuit design to deliver a continuous, spatially and temporally distributed therapeutic pulse pattern across the spinal cord. Results of the study were recently published in Neuromodulation.1
The prospective, multicenter, randomized, single-blind, feasibility study assessed the safety and effectiveness of BIOTRONIK’s new charge-distributed multiphase stimulation paradigm during an extended SCS trial. It included participants with chronic low back and/or leg pain and baseline numerical rating scale (NRS) for overall pain intensity ≥6. After a successful commercial SCS trial, participants were randomized to multiphase SCS therapy (A: approx. 600–1500 Hz or B: approx. 300–600 Hz). Following washout, therapy was delivered via an investigational external pulse generator and existing leads during an 11- to 12–day testing period.
Among the 65 patients completing the study, there was no statistically significant difference in mean NRS reduction or percent pain relief between multiphase therapies A and B. In the at-home setting, 63.9% of participants reported greater pain relief with multiphase than with commercial SCS therapy, along with an increase in average sleep quality and physical activity. Additionally, adverse events were rare, and none were classified by investigators as serious. On average, multiphase required less power than did commercial therapies.1
BENEFIT-02 is part of a comprehensive research program that supports BIOTRONIK’s Prospera SCS System, which received FDA approval in March 2023. Prospera not only features the first and only RESONANCE multiphase stimulation paradigm, it also includes Embrace One™ – a patient-centric care model that enables proactive care* through automatic, objective, daily remote monitoring.
“Former studies have shown good results with previously commercialized SCS technology, yet in practice we are still looking for ways to reduce patient burden and improve outcomes,” said Dr. Leonardo Kapural, pain physician at the Carolinas Pain Institute and Center for Clinical Research in Winston-Salem, North Carolina, USA and Principal Investigator of the BENEFIT-02 study. “This study is particularly exciting because it’s the first in a series to explore how to do that. The short-term multiphase stimulation results here – combined with early findings from the long-term BENEFIT-03 study – show great promise for the future of SCS.”
BENEFIT-03 is the first long-term evaluation of the Prospera SCS system with RESONANCE multiphase stimulation; automatic, daily, objective, device monitoring; and remote programming. Interim results from the ongoing study in Australia support BIOTRONIK Neuro’s proactive care approach to SCS therapy. Interim six-month results recently presented at the ASPN Annual Conference demonstrated significant pain reduction in both in-clinic and at-home settings with less severe disability.2
“As we await additional data from our BENEFIT-03 study, we're excited to see these initial data on the long-term effects of our SCS system,” said BIOTRONIK Neuro President Todd Langevin. “We developed Prospera to offer patients sustainable pain relief – and we believe its proactive care model will have a clinically meaningful impact on lowering long-term failure rates and reducing the service burden of SCS.”
- END -
References
1 Kapural L, Patterson DG, Li S, Hatheway J, Hunter C, Rosen S, Fishman M, Gupta M, Sayed D, Christopher A, Burgher A, McJunkin T, Ross EL, Provenzano D, Amirdelfan K. Multiphase Spinal Cord Stimulation in Participants With Chronic Back or Leg Pain: Results of the BENEFIT-02 Randomized Clinical Trial, Neuromodulation: Technology at the Neural Interface, 2023, https://doi.org/10.1016/j.neurom.2023.05.006.
2 Russo M, Yu J, Mohabbati V, Amirdelfan K, Kapural L, Verrills P. An implantable SCS system with multiphase stimulation and remote device management: Interim 6-month study results. Poster presented at: The American Society of Pain & Neuroscience July 13-16, 2023; Miami Beach, FL.
Prospera SCS system is not CE marked and not available for sale in CE accepting markets or other geographies outside of the United States.
Embrace One is a support platform intended to help manage a patient’s experience with spinal cord stimulation. It is not intended to be used for medical diagnosis or medical treatment.
*BIOTRONIK Neuro’s remote support team may reach out to patients to ensure proper usage of the spinal cord stimulator based on remotely monitored data. BIOTRONIK Neuro does not provide health advice or clinical actions outside the scope of spinal cord stimulator proper usage. This product support is not a replacement for the patient’s responsibility to communicate any medical questions or concerns with the physician’s office.
Newly Published Data Supports Effectiveness of BIOTRONIK Neuro’s RESONANCE™ Stimulation
Results from the BENEFIT-02 trial – the first of its kind to clinically evaluate a multiphase stimulation paradigm – support the effectiveness of RESONANCE multiphase stimulation used in the BIOTRONIK Neuro Prospera™ spinal cord stimulation (SCS) System in the treatment of patients with chronic pain. In contrast to other currently available SCS therapies, RESONANCE requires less power and uses a proprietary integrated circuit design to deliver a continuous, spatially and temporally distributed therapeutic pulse pattern across the spinal cord. Results of the study were recently published in Neuromodulation.1
The prospective, multicenter, randomized, single-blind, feasibility study assessed the safety and effectiveness of BIOTRONIK’s new charge-distributed multiphase stimulation paradigm during an extended SCS trial. It included participants with chronic low back and/or leg pain and baseline numerical rating scale (NRS) for overall pain intensity ≥6. After a successful commercial SCS trial, participants were randomized to multiphase SCS therapy (A: approx. 600–1500 Hz or B: approx. 300–600 Hz). Following washout, therapy was delivered via an investigational external pulse generator and existing leads during an 11- to 12–day testing period.
Among the 65 patients completing the study, there was no statistically significant difference in mean NRS reduction or percent pain relief between multiphase therapies A and B. In the at-home setting, 63.9% of participants reported greater pain relief with multiphase than with commercial SCS therapy, along with an increase in average sleep quality and physical activity. Additionally, adverse events were rare, and none were classified by investigators as serious. On average, multiphase required less power than did commercial therapies.1
BENEFIT-02 is part of a comprehensive research program that supports BIOTRONIK’s Prospera SCS System, which received FDA approval in March 2023. Prospera not only features the first and only RESONANCE multiphase stimulation paradigm, it also includes Embrace One™ – a patient-centric care model that enables proactive care* through automatic, objective, daily remote monitoring.
“Former studies have shown good results with previously commercialized SCS technology, yet in practice we are still looking for ways to reduce patient burden and improve outcomes,” said Dr. Leonardo Kapural, pain physician at the Carolinas Pain Institute and Center for Clinical Research in Winston-Salem, North Carolina, USA and Principal Investigator of the BENEFIT-02 study. “This study is particularly exciting because it’s the first in a series to explore how to do that. The short-term multiphase stimulation results here – combined with early findings from the long-term BENEFIT-03 study – show great promise for the future of SCS.”
BENEFIT-03 is the first long-term evaluation of the Prospera SCS system with RESONANCE multiphase stimulation; automatic, daily, objective, device monitoring; and remote programming. Interim results from the ongoing study in Australia support BIOTRONIK Neuro’s proactive care approach to SCS therapy. Interim six-month results recently presented at the ASPN Annual Conference demonstrated significant pain reduction in both in-clinic and at-home settings with less severe disability.2
“As we await additional data from our BENEFIT-03 study, we're excited to see these initial data on the long-term effects of our SCS system,” said BIOTRONIK Neuro President Todd Langevin. “We developed Prospera to offer patients sustainable pain relief – and we believe its proactive care model will have a clinically meaningful impact on lowering long-term failure rates and reducing the service burden of SCS.”
- END -
References
1 Kapural L, Patterson DG, Li S, Hatheway J, Hunter C, Rosen S, Fishman M, Gupta M, Sayed D, Christopher A, Burgher A, McJunkin T, Ross EL, Provenzano D, Amirdelfan K. Multiphase Spinal Cord Stimulation in Participants With Chronic Back or Leg Pain: Results of the BENEFIT-02 Randomized Clinical Trial, Neuromodulation: Technology at the Neural Interface, 2023, https://doi.org/10.1016/j.neurom.2023.05.006.
2 Russo M, Yu J, Mohabbati V, Amirdelfan K, Kapural L, Verrills P. An implantable SCS system with multiphase stimulation and remote device management: Interim 6-month study results. Poster presented at: The American Society of Pain & Neuroscience July 13-16, 2023; Miami Beach, FL.
Prospera SCS system is not CE marked and not available for sale in CE accepting markets or other geographies outside of the United States.
Embrace One is a support platform intended to help manage a patient’s experience with spinal cord stimulation. It is not intended to be used for medical diagnosis or medical treatment.
*BIOTRONIK Neuro’s remote support team may reach out to patients to ensure proper usage of the spinal cord stimulator based on remotely monitored data. BIOTRONIK Neuro does not provide health advice or clinical actions outside the scope of spinal cord stimulator proper usage. This product support is not a replacement for the patient’s responsibility to communicate any medical questions or concerns with the physician’s office.
Newly Published Data Supports Effectiveness of BIOTRONIK Neuro’s RESONANCE™ Stimulation
Results from the BENEFIT-02 trial – the first of its kind to clinically evaluate a multiphase stimulation paradigm – support the effectiveness of RESONANCE multiphase stimulation used in the BIOTRONIK Neuro Prospera™ spinal cord stimulation (SCS) System in the treatment of patients with chronic pain. In contrast to other currently available SCS therapies, RESONANCE requires less power and uses a proprietary integrated circuit design to deliver a continuous, spatially and temporally distributed therapeutic pulse pattern across the spinal cord. Results of the study were recently published in Neuromodulation.1
The prospective, multicenter, randomized, single-blind, feasibility study assessed the safety and effectiveness of BIOTRONIK’s new charge-distributed multiphase stimulation paradigm during an extended SCS trial. It included participants with chronic low back and/or leg pain and baseline numerical rating scale (NRS) for overall pain intensity ≥6. After a successful commercial SCS trial, participants were randomized to multiphase SCS therapy (A: approx. 600–1500 Hz or B: approx. 300–600 Hz). Following washout, therapy was delivered via an investigational external pulse generator and existing leads during an 11- to 12–day testing period.
Among the 65 patients completing the study, there was no statistically significant difference in mean NRS reduction or percent pain relief between multiphase therapies A and B. In the at-home setting, 63.9% of participants reported greater pain relief with multiphase than with commercial SCS therapy, along with an increase in average sleep quality and physical activity. Additionally, adverse events were rare, and none were classified by investigators as serious. On average, multiphase required less power than did commercial therapies.1
BENEFIT-02 is part of a comprehensive research program that supports BIOTRONIK’s Prospera SCS System, which received FDA approval in March 2023. Prospera not only features the first and only RESONANCE multiphase stimulation paradigm, it also includes Embrace One™ – a patient-centric care model that enables proactive care* through automatic, objective, daily remote monitoring.
“Former studies have shown good results with previously commercialized SCS technology, yet in practice we are still looking for ways to reduce patient burden and improve outcomes,” said Dr. Leonardo Kapural, pain physician at the Carolinas Pain Institute and Center for Clinical Research in Winston-Salem, North Carolina, USA and Principal Investigator of the BENEFIT-02 study. “This study is particularly exciting because it’s the first in a series to explore how to do that. The short-term multiphase stimulation results here – combined with early findings from the long-term BENEFIT-03 study – show great promise for the future of SCS.”
BENEFIT-03 is the first long-term evaluation of the Prospera SCS system with RESONANCE multiphase stimulation; automatic, daily, objective, device monitoring; and remote programming. Interim results from the ongoing study in Australia support BIOTRONIK Neuro’s proactive care approach to SCS therapy. Interim six-month results recently presented at the ASPN Annual Conference demonstrated significant pain reduction in both in-clinic and at-home settings with less severe disability.2
“As we await additional data from our BENEFIT-03 study, we're excited to see these initial data on the long-term effects of our SCS system,” said BIOTRONIK Neuro President Todd Langevin. “We developed Prospera to offer patients sustainable pain relief – and we believe its proactive care model will have a clinically meaningful impact on lowering long-term failure rates and reducing the service burden of SCS.”
- END -
References
1 Kapural L, Patterson DG, Li S, Hatheway J, Hunter C, Rosen S, Fishman M, Gupta M, Sayed D, Christopher A, Burgher A, McJunkin T, Ross EL, Provenzano D, Amirdelfan K. Multiphase Spinal Cord Stimulation in Participants With Chronic Back or Leg Pain: Results of the BENEFIT-02 Randomized Clinical Trial, Neuromodulation: Technology at the Neural Interface, 2023, https://doi.org/10.1016/j.neurom.2023.05.006.
2 Russo M, Yu J, Mohabbati V, Amirdelfan K, Kapural L, Verrills P. An implantable SCS system with multiphase stimulation and remote device management: Interim 6-month study results. Poster presented at: The American Society of Pain & Neuroscience July 13-16, 2023; Miami Beach, FL.
Prospera SCS system is not CE marked and not available for sale in CE accepting markets or other geographies outside of the United States.
Embrace One is a support platform intended to help manage a patient’s experience with spinal cord stimulation. It is not intended to be used for medical diagnosis or medical treatment.
*BIOTRONIK Neuro’s remote support team may reach out to patients to ensure proper usage of the spinal cord stimulator based on remotely monitored data. BIOTRONIK Neuro does not provide health advice or clinical actions outside the scope of spinal cord stimulator proper usage. This product support is not a replacement for the patient’s responsibility to communicate any medical questions or concerns with the physician’s office.
Newly Published Data Supports Effectiveness of BIOTRONIK Neuro’s RESONANCE™ Stimulation
Results from the BENEFIT-02 trial – the first of its kind to clinically evaluate a multiphase stimulation paradigm – support the effectiveness of RESONANCE multiphase stimulation used in the BIOTRONIK Neuro Prospera™ spinal cord stimulation (SCS) System in the treatment of patients with chronic pain. In contrast to other currently available SCS therapies, RESONANCE requires less power and uses a proprietary integrated circuit design to deliver a continuous, spatially and temporally distributed therapeutic pulse pattern across the spinal cord. Results of the study were recently published in Neuromodulation.1
The prospective, multicenter, randomized, single-blind, feasibility study assessed the safety and effectiveness of BIOTRONIK’s new charge-distributed multiphase stimulation paradigm during an extended SCS trial. It included participants with chronic low back and/or leg pain and baseline numerical rating scale (NRS) for overall pain intensity ≥6. After a successful commercial SCS trial, participants were randomized to multiphase SCS therapy (A: approx. 600–1500 Hz or B: approx. 300–600 Hz). Following washout, therapy was delivered via an investigational external pulse generator and existing leads during an 11- to 12–day testing period.
Among the 65 patients completing the study, there was no statistically significant difference in mean NRS reduction or percent pain relief between multiphase therapies A and B. In the at-home setting, 63.9% of participants reported greater pain relief with multiphase than with commercial SCS therapy, along with an increase in average sleep quality and physical activity. Additionally, adverse events were rare, and none were classified by investigators as serious. On average, multiphase required less power than did commercial therapies.1
BENEFIT-02 is part of a comprehensive research program that supports BIOTRONIK’s Prospera SCS System, which received FDA approval in March 2023. Prospera not only features the first and only RESONANCE multiphase stimulation paradigm, it also includes Embrace One™ – a patient-centric care model that enables proactive care* through automatic, objective, daily remote monitoring.
“Former studies have shown good results with previously commercialized SCS technology, yet in practice we are still looking for ways to reduce patient burden and improve outcomes,” said Dr. Leonardo Kapural, pain physician at the Carolinas Pain Institute and Center for Clinical Research in Winston-Salem, North Carolina, USA and Principal Investigator of the BENEFIT-02 study. “This study is particularly exciting because it’s the first in a series to explore how to do that. The short-term multiphase stimulation results here – combined with early findings from the long-term BENEFIT-03 study – show great promise for the future of SCS.”
BENEFIT-03 is the first long-term evaluation of the Prospera SCS system with RESONANCE multiphase stimulation; automatic, daily, objective, device monitoring; and remote programming. Interim results from the ongoing study in Australia support BIOTRONIK Neuro’s proactive care approach to SCS therapy. Interim six-month results recently presented at the ASPN Annual Conference demonstrated significant pain reduction in both in-clinic and at-home settings with less severe disability.2
“As we await additional data from our BENEFIT-03 study, we're excited to see these initial data on the long-term effects of our SCS system,” said BIOTRONIK Neuro President Todd Langevin. “We developed Prospera to offer patients sustainable pain relief – and we believe its proactive care model will have a clinically meaningful impact on lowering long-term failure rates and reducing the service burden of SCS.”
- END -
References
1 Kapural L, Patterson DG, Li S, Hatheway J, Hunter C, Rosen S, Fishman M, Gupta M, Sayed D, Christopher A, Burgher A, McJunkin T, Ross EL, Provenzano D, Amirdelfan K. Multiphase Spinal Cord Stimulation in Participants With Chronic Back or Leg Pain: Results of the BENEFIT-02 Randomized Clinical Trial, Neuromodulation: Technology at the Neural Interface, 2023, https://doi.org/10.1016/j.neurom.2023.05.006.
2 Russo M, Yu J, Mohabbati V, Amirdelfan K, Kapural L, Verrills P. An implantable SCS system with multiphase stimulation and remote device management: Interim 6-month study results. Poster presented at: The American Society of Pain & Neuroscience July 13-16, 2023; Miami Beach, FL.
Prospera SCS system is not CE marked and not available for sale in CE accepting markets or other geographies outside of the United States.
Embrace One is a support platform intended to help manage a patient’s experience with spinal cord stimulation. It is not intended to be used for medical diagnosis or medical treatment.
*BIOTRONIK Neuro’s remote support team may reach out to patients to ensure proper usage of the spinal cord stimulator based on remotely monitored data. BIOTRONIK Neuro does not provide health advice or clinical actions outside the scope of spinal cord stimulator proper usage. This product support is not a replacement for the patient’s responsibility to communicate any medical questions or concerns with the physician’s office.
Five Cardiology Podcasts to Get Into
With being able to listen in while getting something else done – such as running, commuting or cooking – podcasts offer up great ways for us to keep up with what’s going on in every field imaginable – and cardiology is no exception.
An estimated 465 million people now listen to podcasts around the world, including around a third of Americans, almost half of people in Scandinavian countries, and nearly 60 percent of South Koreans – just to name a few examples.
While the plethora of podcast options is huge, health and science podcasts come in eighth and sixth respectively for most popular podcast genres.
Podcast listening is particularly high in the morning, with commuting being a favorite time to listen and 22 percent listening while driving – making it a great medium to consider when trying to stay ahead of the latest cardiology trends and research.
But where do you start?
We picked out a few of our favorites to help you stay ahead of the cardiology curve.
Circulation on the Run
Designed for those for whom time is of the essence, this podcast comes with a 15-minute rundown of the entire episode right at the beginning, covering the most important facts and key messages that’ll be discussed during the show. Busy clinicians on the run can take advantage of the condensed version during their commute – or even, you guessed it – on a short run or other exercise session.
Following the 15-minute digest though, hosts Dr. Carolyn SP Lam, Dr. W. Gregory Hundley and Dr. Peder L. Myhre do a deep dive into the week’s theme, discussing newly released research in greater detail for those who want to get the full rundown.
Recent episodes have discussed new studies in STEMI, pulsed field ablation to treat atrial fibrillation, and a host of pharmacology topics.
Getting to the Heart of Stroke
This three-part podcast series from the American Heart Association zeroes in specifically on issues around stroke.
With clinician hosts changing every week, listeners also hear from nurses and a patient – about stroke diagnostics and long-term ECG monitoring, as well as secondary stroke prevention.
Experts also discuss diversity concerns in the field, such as how care may need to differ for patients of certain minority groups, and how to facilitate better cooperation between cardiologists and neurologists.
CardioNerds Podcast
Hosted by the CardioNerds network founded by Dr. Amit Goyal and Dr. Daniel Ambinder, CardioNerds has put out over 300 episodes since 2019, bringing in numerous fellow “nerds” from many different fields of expertise in cardiology, with a new special guest per week.
CardioNerds makes a special dedicated effort to increase diversity in the field through its invited guests, who may come from groups typically underrepresented in cardiology.
You can also go through the list of episodes either chronologically – or search them by topic – to quickly find an expert podcast on exactly what you’re looking for.
Episodes include a discussion on women’s cardiovascular health with Dr. Martha Gulati, a seven-part series on heart failure with each episode in the series having a different guest to discuss different treatment options, and a rundown of opportunities for international medical graduates in cardiology with Dr. William Zoghbi.
At the Heart of It
The American Heart Association podcast network brings us this gem with Nancy Brown, which combines discussions of heart health with general well-being and inspiring stories. While not strictly a “heart only” podcast, Brown delves into self-care and prioritising health with a number of celebrity guests.
They include Arianna Huffington on getting enough sleep, listening to your body with NFL and NBA reporter Jen Hale, and dealing with heart failure with actor Jason Gray-Stanford.
Love Your Heart
The Cleveland Clinic brings us this podcast focused on everything to do with heart and vascular disease – basically any condition that might affect the chest area.
Exploring everything from prevention to diagnostics and advanced surgical treatments, this podcast has a little something for everyone concerned with the heart, whether they’re patients or expert clinicians.
Episodes explore everything from what type of bioprosthetic heart valves certain patients might need to lipoproteins and Peripheral Artery Disease.
With so many podcasts on offer in general, and no shortage of good cardiology ones, there’s plenty of ways to take advantage of this medium for your own research and development – or even recommending certain editions to patients, to give them as much information as you can about maintaining heart health.
__________________________________________________________________________________
If you’re interested in learning more about BIOTRONIK, read more insightful interviews and articles in our corporate blog.
Five Cardiology Podcasts to Get Into
With being able to listen in while getting something else done – such as running, commuting or cooking – podcasts offer up great ways for us to keep up with what’s going on in every field imaginable – and cardiology is no exception.
An estimated 465 million people now listen to podcasts around the world, including around a third of Americans, almost half of people in Scandinavian countries, and nearly 60 percent of South Koreans – just to name a few examples.
While the plethora of podcast options is huge, health and science podcasts come in eighth and sixth respectively for most popular podcast genres.
Podcast listening is particularly high in the morning, with commuting being a favorite time to listen and 22 percent listening while driving – making it a great medium to consider when trying to stay ahead of the latest cardiology trends and research.
But where do you start?
We picked out a few of our favorites to help you stay ahead of the cardiology curve.
Circulation on the Run
Designed for those for whom time is of the essence, this podcast comes with a 15-minute rundown of the entire episode right at the beginning, covering the most important facts and key messages that’ll be discussed during the show. Busy clinicians on the run can take advantage of the condensed version during their commute – or even, you guessed it – on a short run or other exercise session.
Following the 15-minute digest though, hosts Dr. Carolyn SP Lam, Dr. W. Gregory Hundley and Dr. Peder L. Myhre do a deep dive into the week’s theme, discussing newly released research in greater detail for those who want to get the full rundown.
Recent episodes have discussed new studies in STEMI, pulsed field ablation to treat atrial fibrillation, and a host of pharmacology topics.
Getting to the Heart of Stroke
This three-part podcast series from the American Heart Association zeroes in specifically on issues around stroke.
With clinician hosts changing every week, listeners also hear from nurses and a patient – about stroke diagnostics and long-term ECG monitoring, as well as secondary stroke prevention.
Experts also discuss diversity concerns in the field, such as how care may need to differ for patients of certain minority groups, and how to facilitate better cooperation between cardiologists and neurologists.
CardioNerds Podcast
Hosted by the CardioNerds network founded by Dr. Amit Goyal and Dr. Daniel Ambinder, CardioNerds has put out over 300 episodes since 2019, bringing in numerous fellow “nerds” from many different fields of expertise in cardiology, with a new special guest per week.
CardioNerds makes a special dedicated effort to increase diversity in the field through its invited guests, who may come from groups typically underrepresented in cardiology.
You can also go through the list of episodes either chronologically – or search them by topic – to quickly find an expert podcast on exactly what you’re looking for.
Episodes include a discussion on women’s cardiovascular health with Dr. Martha Gulati, a seven-part series on heart failure with each episode in the series having a different guest to discuss different treatment options, and a rundown of opportunities for international medical graduates in cardiology with Dr. William Zoghbi.
At the Heart of It
The American Heart Association podcast network brings us this gem with Nancy Brown, which combines discussions of heart health with general well-being and inspiring stories. While not strictly a “heart only” podcast, Brown delves into self-care and prioritising health with a number of celebrity guests.
They include Arianna Huffington on getting enough sleep, listening to your body with NFL and NBA reporter Jen Hale, and dealing with heart failure with actor Jason Gray-Stanford.
Love Your Heart
The Cleveland Clinic brings us this podcast focused on everything to do with heart and vascular disease – basically any condition that might affect the chest area.
Exploring everything from prevention to diagnostics and advanced surgical treatments, this podcast has a little something for everyone concerned with the heart, whether they’re patients or expert clinicians.
Episodes explore everything from what type of bioprosthetic heart valves certain patients might need to lipoproteins and Peripheral Artery Disease.
With so many podcasts on offer in general, and no shortage of good cardiology ones, there’s plenty of ways to take advantage of this medium for your own research and development – or even recommending certain editions to patients, to give them as much information as you can about maintaining heart health.
__________________________________________________________________________________
If you’re interested in learning more about BIOTRONIK, read more insightful interviews and articles in our corporate blog.
Five Cardiology Podcasts to Get Into
With being able to listen in while getting something else done – such as running, commuting or cooking – podcasts offer up great ways for us to keep up with what’s going on in every field imaginable – and cardiology is no exception.
An estimated 465 million people now listen to podcasts around the world, including around a third of Americans, almost half of people in Scandinavian countries, and nearly 60 percent of South Koreans – just to name a few examples.
While the plethora of podcast options is huge, health and science podcasts come in eighth and sixth respectively for most popular podcast genres.
Podcast listening is particularly high in the morning, with commuting being a favorite time to listen and 22 percent listening while driving – making it a great medium to consider when trying to stay ahead of the latest cardiology trends and research.
But where do you start?
We picked out a few of our favorites to help you stay ahead of the cardiology curve.
Circulation on the Run
Designed for those for whom time is of the essence, this podcast comes with a 15-minute rundown of the entire episode right at the beginning, covering the most important facts and key messages that’ll be discussed during the show. Busy clinicians on the run can take advantage of the condensed version during their commute – or even, you guessed it – on a short run or other exercise session.
Following the 15-minute digest though, hosts Dr. Carolyn SP Lam, Dr. W. Gregory Hundley and Dr. Peder L. Myhre do a deep dive into the week’s theme, discussing newly released research in greater detail for those who want to get the full rundown.
Recent episodes have discussed new studies in STEMI, pulsed field ablation to treat atrial fibrillation, and a host of pharmacology topics.
Getting to the Heart of Stroke
This three-part podcast series from the American Heart Association zeroes in specifically on issues around stroke.
With clinician hosts changing every week, listeners also hear from nurses and a patient – about stroke diagnostics and long-term ECG monitoring, as well as secondary stroke prevention.
Experts also discuss diversity concerns in the field, such as how care may need to differ for patients of certain minority groups, and how to facilitate better cooperation between cardiologists and neurologists.
CardioNerds Podcast
Hosted by the CardioNerds network founded by Dr. Amit Goyal and Dr. Daniel Ambinder, CardioNerds has put out over 300 episodes since 2019, bringing in numerous fellow “nerds” from many different fields of expertise in cardiology, with a new special guest per week.
CardioNerds makes a special dedicated effort to increase diversity in the field through its invited guests, who may come from groups typically underrepresented in cardiology.
You can also go through the list of episodes either chronologically – or search them by topic – to quickly find an expert podcast on exactly what you’re looking for.
Episodes include a discussion on women’s cardiovascular health with Dr. Martha Gulati, a seven-part series on heart failure with each episode in the series having a different guest to discuss different treatment options, and a rundown of opportunities for international medical graduates in cardiology with Dr. William Zoghbi.
At the Heart of It
The American Heart Association podcast network brings us this gem with Nancy Brown, which combines discussions of heart health with general well-being and inspiring stories. While not strictly a “heart only” podcast, Brown delves into self-care and prioritising health with a number of celebrity guests.
They include Arianna Huffington on getting enough sleep, listening to your body with NFL and NBA reporter Jen Hale, and dealing with heart failure with actor Jason Gray-Stanford.
Love Your Heart
The Cleveland Clinic brings us this podcast focused on everything to do with heart and vascular disease – basically any condition that might affect the chest area.
Exploring everything from prevention to diagnostics and advanced surgical treatments, this podcast has a little something for everyone concerned with the heart, whether they’re patients or expert clinicians.
Episodes explore everything from what type of bioprosthetic heart valves certain patients might need to lipoproteins and Peripheral Artery Disease.
With so many podcasts on offer in general, and no shortage of good cardiology ones, there’s plenty of ways to take advantage of this medium for your own research and development – or even recommending certain editions to patients, to give them as much information as you can about maintaining heart health.
__________________________________________________________________________________
If you’re interested in learning more about BIOTRONIK, read more insightful interviews and articles in our corporate blog.
Five Cardiology Podcasts to Get Into
With being able to listen in while getting something else done – such as running, commuting or cooking – podcasts offer up great ways for us to keep up with what’s going on in every field imaginable – and cardiology is no exception.
An estimated 465 million people now listen to podcasts around the world, including around a third of Americans, almost half of people in Scandinavian countries, and nearly 60 percent of South Koreans – just to name a few examples.
While the plethora of podcast options is huge, health and science podcasts come in eighth and sixth respectively for most popular podcast genres.
Podcast listening is particularly high in the morning, with commuting being a favorite time to listen and 22 percent listening while driving – making it a great medium to consider when trying to stay ahead of the latest cardiology trends and research.
But where do you start?
We picked out a few of our favorites to help you stay ahead of the cardiology curve.
Circulation on the Run
Designed for those for whom time is of the essence, this podcast comes with a 15-minute rundown of the entire episode right at the beginning, covering the most important facts and key messages that’ll be discussed during the show. Busy clinicians on the run can take advantage of the condensed version during their commute – or even, you guessed it – on a short run or other exercise session.
Following the 15-minute digest though, hosts Dr. Carolyn SP Lam, Dr. W. Gregory Hundley and Dr. Peder L. Myhre do a deep dive into the week’s theme, discussing newly released research in greater detail for those who want to get the full rundown.
Recent episodes have discussed new studies in STEMI, pulsed field ablation to treat atrial fibrillation, and a host of pharmacology topics.
Getting to the Heart of Stroke
This three-part podcast series from the American Heart Association zeroes in specifically on issues around stroke.
With clinician hosts changing every week, listeners also hear from nurses and a patient – about stroke diagnostics and long-term ECG monitoring, as well as secondary stroke prevention.
Experts also discuss diversity concerns in the field, such as how care may need to differ for patients of certain minority groups, and how to facilitate better cooperation between cardiologists and neurologists.
CardioNerds Podcast
Hosted by the CardioNerds network founded by Dr. Amit Goyal and Dr. Daniel Ambinder, CardioNerds has put out over 300 episodes since 2019, bringing in numerous fellow “nerds” from many different fields of expertise in cardiology, with a new special guest per week.
CardioNerds makes a special dedicated effort to increase diversity in the field through its invited guests, who may come from groups typically underrepresented in cardiology.
You can also go through the list of episodes either chronologically – or search them by topic – to quickly find an expert podcast on exactly what you’re looking for.
Episodes include a discussion on women’s cardiovascular health with Dr. Martha Gulati, a seven-part series on heart failure with each episode in the series having a different guest to discuss different treatment options, and a rundown of opportunities for international medical graduates in cardiology with Dr. William Zoghbi.
At the Heart of It
The American Heart Association podcast network brings us this gem with Nancy Brown, which combines discussions of heart health with general well-being and inspiring stories. While not strictly a “heart only” podcast, Brown delves into self-care and prioritising health with a number of celebrity guests.
They include Arianna Huffington on getting enough sleep, listening to your body with NFL and NBA reporter Jen Hale, and dealing with heart failure with actor Jason Gray-Stanford.
Love Your Heart
The Cleveland Clinic brings us this podcast focused on everything to do with heart and vascular disease – basically any condition that might affect the chest area.
Exploring everything from prevention to diagnostics and advanced surgical treatments, this podcast has a little something for everyone concerned with the heart, whether they’re patients or expert clinicians.
Episodes explore everything from what type of bioprosthetic heart valves certain patients might need to lipoproteins and Peripheral Artery Disease.
With so many podcasts on offer in general, and no shortage of good cardiology ones, there’s plenty of ways to take advantage of this medium for your own research and development – or even recommending certain editions to patients, to give them as much information as you can about maintaining heart health.
__________________________________________________________________________________
If you’re interested in learning more about BIOTRONIK, read more insightful interviews and articles in our corporate blog.